A Possible Guide as a Tool to Complementary Effects of New Coronavirus

  • Afsaneh Sadremomtaz XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, Netherlands.
  • Javad Hashemi Department of Pathobiology and Laboratory Sciences, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Adeleh Sahebnasagh Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Seyed Mohammad Nabavi Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Zayana M.Al-Dahmani XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, Netherlands.
  • Shayesteh Gheibi Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Bita Shahrami Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Reza Mosaed Department of Anesthesiology and Intensive Care, School of Medicine, Aja University of Medical Sciences, Tehran, Iran
  • Peyman Arfa Burn Intensive Care Unit, Shahid Motahari Burn Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Soheil Roshanzamiri Burn Intensive Care Unit, Shahid Motahari Burn Hospital, Iran University of Medical Sciences, Tehran, Iran
  • Mojtaba Mojtahedzadeh Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Keywords: Sars-CoV-2; Drugs; Adjuvant therapies

Abstract

At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage. Ultimately the minority of patients progress to stage III with high mortality.

The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak.

Published
2021-10-31
Section
Articles